BML (BMLKF) Moat Score: 2/10 (As of Jul. 02, 2026)


BMLKF BML Inc BMLKF
73 GF Score
Price $25.21
GF Value $26.44
! 2 Warning Signs
View Full Analysis

What is BML Moat Score?

BML BMLKF 73 Moat Score is 2 as of Jul. 02, 2026. GuruFocus rates BMLKF with a GF Score™ of 73/100 and a GF Value™ of $26.44. The stock has 2 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, BML ranks better than 69.44% on this metric.

BML has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

BML has No Moat: BML Inc shows no discernible moat with limited market presence and no significant competitive advantages. The company lacks network effects, strong brand strength, and durable cost advantages. It also does not benefit from significant regulatory barriers or exclusive licenses, making its competitive position weak and transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BML might have No Moat - Very weak/transient advantages.

BML  (OTCPK:BMLKF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BML Moat Score Related Terms

BMLKF vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, BML's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BML Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BML's Moat Score distribution charts can be found below:

* The bar in red indicates where BML's Moat Score falls into.


BMLKF
73GF Score
BML Inc BMLKF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
BML (BMLKF) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BML ranks #66 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 30.6%.
Is BML's Moat Score too high?
BML's current Moat Score is 2. Based on the distribution chart, BML ranks #66 out of 216 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BML has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does BML's Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #66 out of 216 companies for Moat Score. This puts BML in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. BML's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current Moat Score of 2. The stock's GF Value™ is $26.44, compared to a current price of $25.21 — trading 4.7% below its estimated fair value. The current Moat Score is 2. BML's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BML (BMLKF), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BML (BMLKF) Overvalued in 2026?

Based on GuruFocus' analysis, BML stock appears to be undervalued. The current stock price of $25.21 is trading 4.7% below its estimated GF Value™ of $26.44.

Key valuation signals for BMLKF:

  • Moat Score: 2
  • GF Value™: $26.44 vs. price of $25.21 (4.7% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BML Business Description

Other Exchanges 4694:Japan
Address 5-21-3 Sendagaya, Shibuya-ku, Tokyo, JPN, 1510051
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
73GF Score

Get the complete analysis for BMLKF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.21
Price
$26.44
GF Value